CD72 nanoCARs for the treatment of refractory pediatric B-cell acute lymphoblastic leukemia

  • Post author:
  • Post category:

Translational Candidate CD72-targeting chimeric antigen receptor (CAR) T cells incorporating fully synthetic nanobodies Area of Impact Pediatric B-cell acute lymphoblastic leukemia refractory to currently available treatments without other potentially curative…

Continue ReadingCD72 nanoCARs for the treatment of refractory pediatric B-cell acute lymphoblastic leukemia

Development of novel synNotch CART cell therapy in patients with recurrent EGFRvIII+ glioblastoma

  • Post author:
  • Post category:

Translational Candidate Human T cells transduced with a lentiviral vector encoding anti-EGFRvIII synNotch-primed anti-EphA2/IL-13Rα2 chimeric antigen receptor. Area of Impact Glioblastoma is the most common malignant brain tumor, affecting approximately…

Continue ReadingDevelopment of novel synNotch CART cell therapy in patients with recurrent EGFRvIII+ glioblastoma

Development of novel synNotch CART cell therapy in patients with recurrent EGFRvIII+ glioblastoma

  • Post author:
  • Post category:

Translational Candidate Human T cells transduced with a lentiviral vector encoding anti-EGFRvIII synNotch-primed anti-EphA2/IL-13Rα2 chimeric antigen receptor. Area of Impact Glioblastoma is the most common malignant brain tumor, affecting approximately…

Continue ReadingDevelopment of novel synNotch CART cell therapy in patients with recurrent EGFRvIII+ glioblastoma